Hangzhou Sumgen Biotech Co., Ltd (hereinafter “Sumgen) has recently completed a series A+ funding of tens of millions RMB exclusively with China National Biotech Group (hereinafter “CNBG”). This is
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter “Sumgen”) recently announced that Sumgen\'s Antibody Drug CMC R&D Center in Hangzhou Binjiang Tianhe High-Tech Park is officially established. Thi
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter \"Sumgen”) has recently announced that their proprietary recombinant anti-PD-1 fully human monoclonal antibody injection (SG001), a national Class I n
On Jul. 26, 2018, Sumgen completed a 50 million R......
On Jul. 24, 2018, Hangzhou Sumgen Biotech Co., Ltd. (hereinafter “Sumgen”) announced that IND (Investigational New Drug) application of their proprietary recombinant anti-PD-1 fully human monoc
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044